Board of Directors

The Board of Directors (BOD) provides strategic guidance and direction for Biological Dynamics' commercial operations. The BOD is comprised of renowned industry leaders from medical business, and venture arenas.

Irwin M. Jacobs, ScD

Irwin Jacobs is a founding Chairman and CEO Emeritus of Qualcomm and Chairman Emeritus of the Salk Institute for Biological Studies and one of Biological Dynamics earliest investors. Dr. Jacobs bring to the BoD immense amount of experience of building and commercializing technology at global scale. He has a deep understanding of our ability to transform the way cancer is detected and diagnosed. 

As co-founder of Qualcomm, Jacobs led the commercialization of CDMA, a key technological component of advanced voice and data wireless communications now used by hundreds of millions of consumers worldwide. Jacobs’ stellar achievements in communications technology began during his tenure as an associate professor at MIT, where he received his Sc.D. in Electrical Engineering in 1959 and developed a life-long passion for information theory. He has received numerous recognitions and awards, including the National Medal of Technology, the IEEE Alexander Graham Bell medal, and the Franklin Institute Bower Award in Business Leadership. 

Martin J. Wygod 

Martin Wygod has immense amount of expertise in commercializing cutting-edge business models. As the founder of Medco Containment Services, Martin Wygod pioneered the pharmacy benefit management (PBM) industry and reduced the cost of prescription drugs while improving patient health outcomes. Medco was the largest PBM company when it was acquired by Merck in 1993 for $6 billion.

Most recently, Wygod was the Chairman of the Board of WebMD Health for over 15 years. Under his direction, WebMD became the leading source of health information services for consumers, healthcare professionals, employers, and health plans and a valued partner to many pharmaceutical, medical device companies, and health plans. WebMD was acquired by a KKR portfolio company for $2.8 billion in 2017. 

John L. "Kip" Miller

Mr. Miller is an accomplished executive with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and BD Biosciences.

Until 2011, he served as President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics. Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the $500M Biodiscovery division, a leading developer of life science tools and enabling technologies for biomedical research, pharmaceutical drug discovery services, and transplantation diagnostics. Earlier in his career Mr. Miller held a variety of responsibilities at BD Biosciences including General Manager and Vice President of Sales and Services of the Americas.

Mr. Miller is actively involved with early life sciences companies. He is a former board member of Tonbo Biosciences (co-founder), Solulink, Cellector, Celsee, and Firefly Bioworks. Active board roles include Independent Director at Biological Dynamics and Non-Executive Chairman at Roswell Biotechnologies.

Paul V Maier, MBA

Mr. Maier brings strong senior operational and financial experience, as well as an impressive track record of shaping and expanding life science businesses, to Biological Dynamics board.  He has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies, where he raised over $1.5 Billion in equity and debt financing and led a number of IPO and M&A transactions.
As Chief Financial Officer of Sequenom, Inc. from November 2009 through June 2014, Mr. Maier was instrumental in raising more than $360 million in equity and debt financing and commercializing Sequenom’s molecular diagnostics segment. He served as Chief Financial Officer at Ligand Pharmaceuticals Inc. from 1992 to 2007 where he helped build the venture-stage company into a commercial, integrated biopharmaceutical organization and ICN Pharmaceuticals (now Valeant Pharmaceuticals International, Inc.) where he served in various senior finance and general management roles.

Mr. Maier currently serves on the Board of Apricus Biosciences, International Stem Cell, MabVax Therapeutics, and Ritter Pharmaceuticals.  Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Raj Krishnan, PhD - CEO

Dr. Raj Krishnan founded Biological Dynamics in 2010 with the mission to revolutionize the approach toward the diagnosis and treatment of high burden diseases- the manifestation of his long desire to help people with cancer and save lives. Receiving his Ph.D. in Bioengineering from UC San Diego, Raj moved to build a company based on the technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics for the purpose of blood-based diagnosis.

For the last several years, under Raj's vision and guidance, Biological Dynamics has transformed from concept to early stage startup, and then to one of the most innovative diagnostic companies in Southern California. His passion and conviction has led BioDyn through 3 rounds of funding, securing over $30M in total. Raj has published several papers on AC Electrokinetics and was recently named to the Top 30 under 30 scientists by Forbes magazine.